Many proteins carry post-translational modifications — phosphorylation, methylation, acetylation, glycosylation, ubiquitination and others — and the presence or absence of a modification at a specific site often determines what the protein does. Detecting a modification requires an antibody that recognizes the modified form while ignoring the far more abundant unmodified protein. That specificity is the entire challenge of a post-translational modification (PTM) antibody project.
Two levels of specificity are possible. A pan-modification antibody reports the overall level of a modification across a proteome or a lysate, while a site-specific antibody distinguishes a modification at one particular residue of one protein. Site-specific reagents demand far more careful antigen design and screening, and some modification types are harder to target than others: phosphorylation antibodies are the most established, acetylation and methylation become progressively more difficult, and glycosylation varies strongly with the size and position of the attached glycan.
We design and prepare PTM-specific antibodies using careful antigen design and negative screening to suppress recognition of the unmodified protein, with the level of specificity agreed at the start of the project so the reagent matches the question.
| Requirement | Antibody type | Typical deliverable |
| Overall modification level in a sample | Pan-modification antibody | A reagent reporting total modification across the sample |
| One modification at a defined residue | Site-specific antibody (often monoclonal) | A reagent distinguishing modified from unmodified at that site |
| Modification | Practical note |
| Phosphorylation | The most established and reliable target for site-specific antibodies |
| Acetylation | More demanding than phosphorylation; specificity requires careful design |
| Methylation | The most difficult for site specificity, since the change is chemically small |
| Glycosylation | Variable; difficulty depends on glycan size and position |
A PTM antibody is only useful if it can tell the modified protein from the unmodified one, so we treat specificity as the specification and screen against it. We choose the antigen design and the specificity level that fit the question, use negative screening to remove cross-reactive candidates, and are straightforward about where a particular modification is intrinsically difficult, so the project scope matches reality rather than expectation.